These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35403606)

  • 1. c-Met-targeted chimeric antigen receptor T cells inhibit hepatocellular carcinoma cells
    Huang X; Guo J; Li T; Jia L; Tang X; Zhu J; Tang Q; Feng Z
    J Biomed Res; 2021 Dec; 36(1):10-21. PubMed ID: 35403606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HGF-Based CAR-T Cells Target Hepatocellular Carcinoma Cells That Express High Levels of c-Met.
    Ma H; Wei W; Liang D; Xu X; Yang D; Wang Q; Wang Y; Wei Q; Sun B; Zhao X
    Immunol Invest; 2023 Nov; 52(6):735-748. PubMed ID: 37409941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine kinase signaling-independent MET-targeting with CAR-T cells.
    Qin A; Qin Y; Lee J; Musket A; Ying M; Krenciute G; Marincola FM; Yao ZQ; Musich PR; Xie Q
    J Transl Med; 2023 Oct; 21(1):682. PubMed ID: 37779207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. c-Met-Specific Chimeric Antigen Receptor T Cells Demonstrate Anti-Tumor Effect in c-Met Positive Gastric Cancer.
    Kang CH; Kim Y; Lee DY; Choi SU; Lee HK; Park CH
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DLK1-directed chimeric antigen receptor T-cell therapy for hepatocellular carcinoma.
    Zhai Y; He K; Huang L; Shang X; Wang G; Yuan G; Han ZG
    Liver Int; 2022 Nov; 42(11):2524-2537. PubMed ID: 36002393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. c-Met specific CAR-T cells as a targeted therapy for non-small cell lung cancer cell A549.
    Min J; Long C; Zhang L; Duan J; Fan H; Chu F; Li Z
    Bioengineered; 2022 Apr; 13(4):9216-9232. PubMed ID: 35378051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells.
    Sun B; Yang D; Dai H; Liu X; Jia R; Cui X; Li W; Cai C; Xu J; Zhao X
    Cancer Immunol Res; 2019 Nov; 7(11):1813-1823. PubMed ID: 31484657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer.
    Chen C; Gu YM; Zhang F; Zhang ZC; Zhang YT; He YD; Wang L; Zhou N; Tang FT; Liu HJ; Li YM
    Oncoimmunology; 2021 Mar; 10(1):1901434. PubMed ID: 33854821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Construction and function of Glypican-3-targeted fourth-generation chimeric antigen receptor T cells (secreting IL-7 and CCL19)].
    Huang W; Liu Y; Hu Y; Gao J
    Sheng Wu Gong Cheng Xue Bao; 2020 May; 36(5):979-991. PubMed ID: 32567281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Study on construction of c-Met specific CAR-T cells and its killing effect on non-small cell lung carcinoma].
    Min JT; Zhang L; Long CR; Fan HL; Li ZZ
    Zhonghua Zhong Liu Za Zhi; 2023 Apr; 45(4):322-329. PubMed ID: 37078213
    [No Abstract]   [Full Text] [Related]  

  • 12. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.
    Shen CJ; Yang YX; Han EQ; Cao N; Wang YF; Wang Y; Zhao YY; Zhao LM; Cui J; Gupta P; Wong AJ; Han SY
    J Hematol Oncol; 2013 May; 6():33. PubMed ID: 23656794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma.
    Guo X; Jiang H; Shi B; Zhou M; Zhang H; Shi Z; Du G; Luo H; Wu X; Wang Y; Sun R; Li Z
    Front Pharmacol; 2018; 9():1118. PubMed ID: 30327605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity.
    Li W; Guo L; Rathi P; Marinova E; Gao X; Wu MF; Liu H; Dotti G; Gottschalk S; Metelitsa LS; Heczey A
    Hum Gene Ther; 2017 May; 28(5):437-448. PubMed ID: 27530312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation.
    Halim L; Das KK; Larcombe-Young D; Ajina A; Candelli A; Benjamin R; Dillon R; Davies DM; Maher J
    Front Immunol; 2022; 13():836549. PubMed ID: 35222427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo.
    Tang X; Zhou Y; Li W; Tang Q; Chen R; Zhu J; Feng Z
    J Biomed Res; 2014 Nov; 28(6):468-75. PubMed ID: 25469116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GPC3-targeted CAR-T cells secreting B7H3-targeted BiTE exhibit potent cytotoxicity activity against hepatocellular carcinoma cell in the in vitro assay.
    Cao G; Zhang G; Liu M; Liu J; Wang Q; Zhu L; Wan X
    Biochem Biophys Rep; 2022 Sep; 31():101324. PubMed ID: 36032401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.
    Gao H; Li K; Tu H; Pan X; Jiang H; Shi B; Kong J; Wang H; Yang S; Gu J; Li Z
    Clin Cancer Res; 2014 Dec; 20(24):6418-28. PubMed ID: 25320357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNAM1 and 2B4 Costimulatory Domains Enhance the Cytotoxicity of Anti-GPC3 Chimeric Antigen Receptor-Modified Natural Killer Cells Against Hepatocellular Cancer Cells in vitro.
    Huang Y; Zeng J; Liu T; Xu Q; Song X; Zeng J
    Cancer Manag Res; 2020; 12():3247-3255. PubMed ID: 32440221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of GPC3 and EGFR-dual-targeting chimeric antigen receptor-T cells for adoptive T cell therapy.
    Li K; Qian S; Huang M; Chen M; Peng L; Liu J; Xu W; Xu J
    Am J Transl Res; 2021; 13(1):156-167. PubMed ID: 33527015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.